More earnings analysis: https://betafinch.com
Groups: HEALTHCARE (https://betafinch.com/groups/HEALTHCARE)
──────────
# Beta Finch Podcast Script: Medtronic Q4 2026 Earnings
**ALEX:** Welcome back to Beta Finch, your AI-powered earnings breakdown where we dive deep into the numbers that matter. I'm Alex, and I'm joined as always by my co-host Jordan. Today we're unpacking Medtronic's fourth quarter 2026 results, and folks, this is a company that's clearly hitting its stride.
Before we dive in, I need to share an important disclaimer: This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.
**JORDAN:** Thanks Alex, and wow - where do we even start with Medtronic? These numbers are impressive. The company just posted $9.8 billion in Q4 revenue, up nearly 10% reported and 6.6% organically. But here's what really caught my attention - this caps off their strongest annual performance in a decade.
**ALEX:** That's right, Jordan. For the full fiscal year, they hit $36.4 billion in revenue with 8.4% reported growth and 5.8% organic growth. CEO Geoff Martha was clearly proud of these results, calling it a reflection of their "commitment to operational rigor" while investing in durable growth. But let's talk about what's really driving this performance.
**JORDAN:** The star of the show has got to be their Cardiac Ablation Solutions business - or CAS. This division delivered 78% worldwide growth and gained 8 points of U.S. market share. Their PFA technology saw 145% global growth, with their Sphere-9 catheter continuing to show "broad versatility," as Martha put it.
**ALEX:** And here's what's really exciting about CAS - they're still in the "early innings," as CFO Thierry Pieton noted. The company increased their installed base by 40% just in the fourth quarter alone. They're now annualizing over $2 billion in revenue and are on track to hit that $2 billion trailing mark in the first quarter of fiscal 2027. That's massive scale in a high-growth market.
**JORDAN:** What I found fascinating was Martha's comment about "completely surrounding the electrophysiology space." They're not just selling one product - they're building an entire ecosystem. They launched Sphere-9 in Japan, got FDA approval for a U.S. VT pivotal trial, and even announced two targeted investments in ICE catheter technology this morning.
**ALEX:** Speaking of investments, let's talk about their capital allocation strategy because this is where you really see the company's long-term vision. In Q4 alone, they closed or announced nearly $2 billion in additional investments through M&A and venture deals. They acquired CathWorks for their AI-powered FFRangio system, announced plans to buy Scientia for neurovascular guidewire tech, and made investments in everything from chronic pain management to pulmonary artery denervation.
**JORDAN:** That's a great point, Alex. And it's not just about buying technology - it's about strategic positioning. Take their Symplicity Spyral system for treating hypertension. This business is now annualizing at $100 million, and they've doubled their weekly procedure volumes since getting the NCD coverage decision. Martha emphasized that 18 million Americans still have uncontrolled hypertension despite multiple medications - that's a massive addressable market.
**ALEX:** Let's shift to the numbers that investors will be watching closely. For fiscal 2027, Medtronic is guiding to organic revenue growth of 6.75% to 7.25%. Now, there's an extra selling week baked into that, which adds about 125 basis points, but even adjusting for that, we're looking at solid mid-single-digit growth acceleration.
**JORDAN:** The guidance is particularly interesting because of how they're handling the MiniMed diabetes business. They completed the IPO in March, but
This episode includes AI-generated content.
続きを読む
一部表示
2026/06/049 分